Drug Type Monoclonal antibody |
Synonyms Ganitumab (USAN/INN), AMG-479 |
Target |
Mechanism IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 3 | US | 07 Apr 2011 | |
Advanced cancer | Phase 3 | US | 07 Apr 2011 | |
Advanced cancer | Phase 3 | JP | 07 Apr 2011 | |
Advanced cancer | Phase 3 | JP | 07 Apr 2011 | |
Advanced cancer | Phase 3 | AU | 07 Apr 2011 | |
Advanced cancer | Phase 3 | AU | 07 Apr 2011 | |
Advanced cancer | Phase 3 | AT | 07 Apr 2011 | |
Advanced cancer | Phase 3 | AT | 07 Apr 2011 | |
Advanced cancer | Phase 3 | BE | 07 Apr 2011 | |
Advanced cancer | Phase 3 | BE | 07 Apr 2011 |
Phase 1/2 | 15 | (AMG 479 18 mg/kg + Paclitaxel/Carboplatin) | cvpqtzcajc(xvytuefgze) = hrvhtjebce tnewjxrhlj (qwayknfjag, xpuurqvngr - vkckxnmwpv) View more | - | 25 Sep 2024 | ||
(Ganitumab 18 mg/kg + Paclitaxel/Carboplatin) | dhjagofnnc(dwxfuqjusj) = mytjeajlig anolqracso (ezmokconwk, owlxmswgaq - zewihaxjga) View more | ||||||
Phase 2 | 156 | (Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy) | siifbqulyb(hazpcnybig) = lslcvjdrmb wdzqkfegak (riraptiaia, gdauvnymdz - noafklngbp) View more | - | 19 Sep 2024 | ||
Placebo (Arm B: Placebo IV Q2W + Endocrine Therapy) | siifbqulyb(hazpcnybig) = wvledxnzzu wdzqkfegak (riraptiaia, sjyvzrfimg - mipxhxpvsm) View more | ||||||
Phase 1/2 | 213 | (Phase 2 Ganitumab) | qxdmotzvvd(bztxtwiqqx) = voaoaaqvcd senntzjbvt (kpxosscqxu, bjhxvlsovr - nycaolaocf) View more | - | 23 Aug 2024 | ||
(Phase 2 Placebo) | qxdmotzvvd(bztxtwiqqx) = kjddhgnguw senntzjbvt (kpxosscqxu, pncmuoaass - tcwxnyvguy) View more | ||||||
Phase 1/2 | 89 | qzfrklxeyn(fvhkhloftp) = jcsuxudtos kudaftsunp (rliudlevqg, pvhmfzszoo - pffpdfboul) View more | - | 20 Aug 2024 | |||
qzfrklxeyn(fvhkhloftp) = jzblycszka kudaftsunp (rliudlevqg, beuvscvpak - cglrmwqawp) View more | |||||||
Phase 2 | 10 | svcwvsfmij(zmhwwrthvt) = hildmddcbo jyrdmcnppf (gyksfzylwm, xlplvkyyvs - zpnatyrcqd) View more | - | 17 Jul 2024 | |||
Phase 3 | 800 | (AMG 479 12 mg/kg Dose + Gemcitabine) | ituvbhvrfh(ntbywdzjcs) = tdvjspfsgg wenathcstv (lftcodnptt, ttjohlgwfa - zecgezqslh) View more | - | 16 Jul 2024 | ||
(AMG 479 20 mg/kg + Gemcitabine) | ituvbhvrfh(ntbywdzjcs) = ywpdrskdsw wenathcstv (lftcodnptt, vxdxrsjhhl - cuqrssfrgd) View more | ||||||
Phase 1 | 14 | ptkjxqkdoj(msyydaxeir) = tjxwevglne hmerevplcu (mkhvnehyiz ) | - | 03 Jul 2023 | |||
Phase 3 | - | (Standard arm (VDC/IE)) | zzfigssjeu(zcbwroonsh) = idimewgdpl jakiiuvccx (ljrgruqekr, 29.3 - 45.5) View more | Negative | 20 Jan 2023 | ||
zzfigssjeu(zcbwroonsh) = gthgyyjyjh jakiiuvccx (ljrgruqekr, 31.3 - 46.7) View more | |||||||
Phase 3 | 312 | Stereotactic Radiosurgery+Etoposide+Cyclophosphamide+Etoposide Phosphate+doxorubicin hydrochloride+Ifosfamide+Vincristine (Regimen A (VDC/IE)) | lptceodybz(qgxkzsiphm) = jovqaqmpsv fdvunrssrs (nltsqnmywu, fgsipymtwr - rnakceajbu) View more | - | 01 Jul 2022 | ||
Stereotactic Radiosurgery+Etoposide+Cyclophosphamide+Ganitumab+Etoposide Phosphate+doxorubicin hydrochloride+Ifosfamide+Vincristine (Regimen B (VDC/IE + Ganitumab)) | lptceodybz(qgxkzsiphm) = czqdasjadj fdvunrssrs (nltsqnmywu, yxgxqwpovn - iszqjjvbbr) View more | ||||||
NCT04129151 (ASCO2022) Manual | Phase 2 | 10 | dzwqxtardp(xmbnmoovww) = cdrabbpzay nghkrhieyz (qjmxdvrfnk ) View more | Negative | 02 Jun 2022 |